Loading clinical trials...

UNKNOWNPHASE1

Intratracheal Umbilical Cord-derived Mesenchymal Stem Cells for Severe Bronchopulmonary Dysplasia

Intratracheal Instillation of Umbilical Cord-derived Mesenchymal Stem Cells as a Rescue Treatment for Severe Bronchopulmonary Dysplasia

NCT01207869•China Medical University Hospital

View on ClinicalTrials.gov

Summary

Mesenchymal stem cells (MSCs) have been reported to be effective to prevent alveolar growth arrest in experimental bronchopulmonary dysplasia (BPD). The aim is to treat the extremely premature infant with severe BPD to establish whether intratracheal instillation of umbilical cord-derived MSCs (ucMSCs) is safe and effective as a rescue treatment for severe BPD.

Eligibility

Age

0 - 0 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•severe BPD, defined by the National Institute of Child Health and Human Development workshop, who conventional therapies (including furosemide and theophylline, and HFO ventilation) has failed

Exclusion Criteria

•severe congenital anomalies
•severe intraventricular hemorrhage ≥ grade 3 or cystic periventricular leukomalacia.

Locations (1)

China Medical University Hospital

Taichung, Taiwan

Key Dates

Start Date

July 1, 2010

Primary Completion Date

June 1, 2012

Completion Date

July 1, 2012

Last Updated

September 23, 2010

Enrollment

ESTIMATED participants

Conditions

Bronchopulmonary DysplasiaExtremely Premature InfantsSevere BPD That Conventional Therapies Has FailedNo Severe Congenital Anomaliesno Severe IVH Neither Cystic PVL

Interventions

ucMSCs

BIOLOGICAL

Normal saline

OTHER

IVIG Trial for the Treatment of Bronchopulmonary Dysplasia

NCT06925360

Bronchopulmonary Dysplasia

View study

RECRUITING

Reversibility of Bronchial Obstruction in Children Born Preterm

NCT06110481

Bronchopulmonary DysplasiaChronic Lung Disease of Prematurity+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 23, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Intratracheal Umbilical Cord-derived Mesenchymal Stem Cells for Severe Bronchopulmonary Dysplasia

Inclusion Criteria

Exclusion Criteria

IVIG Trial for the Treatment of Bronchopulmonary Dysplasia

Reversibility of Bronchial Obstruction in Children Born Preterm

The Role of Volatile Organic Compounds (VOCs), Airway Mucins and the Microbiome in the Early Prediction of Bronchopulmonary Dysplasia (BPD)

Gastric Feeding Versus Transpyloric Feeding in Infants with Severe Bronchopulmonary Dysplasia, a Crossover Study

Comparison of INRECSURE and LISA in Preterm Neonates With RDS

Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia